ORIC PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ORIC PHARMACEUTICALS, INC. (ORIC) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $7.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $7.09M, a 7.86% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.90M, a 5.25% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $5.63M, a 11.37% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $6.57M, a 31.59% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $25.04M, a 23.87% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $20.21M, a 32.75% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $15.23M, a 5.30% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $14.46M, a 12.50% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.09M 10-Q · filed 2026-08-03 | $13.99M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2026-03-31 | $6.90M 10-Q · filed 2026-08-03 | |||
| 2025-12-31 | $25.04M 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $5.63M 10-Q · filed 2025-11-13 | $12.21M derived: sum of 2 quarters · filed 2026-08-03 | $18.76M derived: sum of 3 quarters · filed 2026-08-03 | |
| 2025-06-30 | $6.57M 10-Q · filed 2026-08-03 | $13.13M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2025-03-31 | $6.55M 10-Q · filed 2026-08-03 | |||
| 2024-12-31 | $20.21M 10-K · filed 2026-02-23 | |||
| 2024-09-30 | $5.06M 10-Q · filed 2025-11-13 | $10.05M derived: sum of 2 quarters · filed 2025-11-13 | $15.01M derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | $5.00M 10-Q · filed 2025-11-13 | $9.95M derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $4.96M 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $15.23M 10-K · filed 2025-02-18 | |||
| 2023-09-30 | $3.86M 10-Q · filed 2024-11-12 | $7.69M derived: sum of 2 quarters · filed 2024-11-12 | $11.30M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $3.83M 10-Q · filed 2024-11-12 | $7.44M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $3.61M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $14.46M 10-K · filed 2024-03-11 | |||
| 2022-09-30 | $3.29M 10-Q · filed 2023-11-06 | $7.38M derived: sum of 2 quarters · filed 2023-11-06 | $11.33M derived: sum of 3 quarters · filed 2023-11-06 | |
| 2022-06-30 | $4.09M 10-Q · filed 2023-11-06 | $8.04M derived: sum of 2 quarters · filed 2023-11-06 | ||
| 2022-03-31 | $3.94M 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $12.85M 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $3.40M 10-Q · filed 2022-11-07 | $6.61M derived: sum of 2 quarters · filed 2022-11-07 | $9.35M derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $3.21M 10-Q · filed 2022-11-07 | $5.96M derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | $2.74M 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | $5.28M 10-K · filed 2022-03-21 | |||
| 2020-09-30 | $1.68M 10-Q · filed 2021-11-08 | $3.06M derived: sum of 2 quarters · filed 2021-11-08 | $3.59M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $1.38M 10-Q · filed 2021-11-08 | $1.91M derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2020-03-31 | $527.00K 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $1.09M 10-K · filed 2022-03-21 | |||
| 2019-09-30 | $271.00K 10-Q · filed 2020-11-05 | $461.00K derived: sum of 2 quarters · filed 2020-11-05 | $652.00K derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $190.00K 10-Q · filed 2020-11-05 | $381.00K derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $191.00K 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $469.00K 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |